Login Register Cart 0
Generic placeholder image

Current Nutrition & Food Science

Editor-in-Chief

ISSN (Print): 1573-4013
ISSN (Online): 2212-3881

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Probiotics as an Adjunct Approach to the Prevention and Treatment of Colon Cancer: A Review

Author(s): Akash Kumar, Nandani Goyal, Jhilam Pramanik, Yashna Bawa, Sudarshan Singh* and Bhupendra Prajapati*

Volume 20, Issue 9, 2024

Published on: 19 January, 2024

Page: [1086 - 1099] Pages: 14

DOI: 10.2174/0115734013270901231124063616

Price: $65

Open Access Journals Promotions 2
Abstract

One out of every six people in the world is suffering from cancer disease. The major causes of cancer are high consumption of tobacco, high body mass index, and alcoholic beverages with low intake of a healthy diet and limited physical activity. Colon cancer is one of the leading causes of cancer-related morbidity worldwide. In the past few years, probiotics have drawn a lot of interest as potential preventive and therapeutic anticancer agents. This literature review addressed both human and animal research that has explored the association between probiotics and colon cancer. Probiotic administration has remarkable potential for the prevention and treatment of colon cancer through various mechanisms such as inhibiting the growth of cancer cells via apoptosis, improving immune activity, restoring gut microbiota, improving intestinal barrier properties, synthesizing anticarcinogenic compounds, and degrading carcinogenic compounds. Therefore, probiotics emerge as an adjunct therapy, holding the potential to significantly reduce the risk of colorectal cancer.

Keywords: Probiotics, colorectal cancer, intestinal microbiome, Lactobacillus, dysbiosis, cytokines.

« Previous Next »
Graphical Abstract

[1]
Chen G. The role of the gut microbiome in colorectal cancer. Clin Colon Rectal Surg 2018; 31(3): 192-8.
[http://dx.doi.org/10.1055/s-0037-1602239] [PMID: 29720905]
[2]
Farhana L, Banerjee HN, Verma M, Majumdar APN. Role of microbiome in carcinogenesis process and epigenetic regulation of colorectal cancer. Methods Mol Biol 2018; 1856: 35-55.
[http://dx.doi.org/10.1007/978-1-4939-8751-1_3] [PMID: 30178245]
[3]
WHO. Cancer. 2022. Available From: https://www.who.int/news-room/fact-sheets/detail/cancer
[4]
WHO. Colorectal cancer. 2023. Available From: https://www.who.int/news-room/fact-sheets/detail/colorectal-cancer
[5]
Drago L. Probiotics and colon cancer. Microorganisms 2019; 7(3): 667.
[http://dx.doi.org/10.3390/microorganisms7030066]
[6]
Singh S, Singh M, Gaur S. Probiotics as multifaceted oral vaccines against colon cancer: A review. Front Immunol 2022; 13: 1002674.
[http://dx.doi.org/10.3389/fimmu.2022.1002674] [PMID: 36263037]
[7]
Kumar A, Pramanik J, Goyal N, Chauhan D, Sivamaruthi BS, Prajapati BG. Gut microbiota in anxiety and depression: Unveiling the relationships and management options. Pharmaceuticals (Basel) 2023; 16(4): 565.
[http://dx.doi.org/10.3390/ph16040565]
[8]
Shah A, Dubey A, Hemnani V, Gala D, Kalbande DR. Smart farming system: Crop yield prediction using regression techniques. Lecture Notes on Data Engineering and Communications Technologies 2018; 19: 49-56.
[http://dx.doi.org/10.1007/978-981-10-8339-6_6]
[9]
Vangay P, Johnson AJ, Ward TL, et al. US immigration westernizes the human gut microbiome. Cell 2018; 175(4): 962-972.e10.
[http://dx.doi.org/10.1016/j.cell.2018.10.029] [PMID: 30388453]
[10]
Deschasaux M, Bouter KE, Prodan A, et al. Depicting the composition of gut microbiota in a population with varied ethnic origins but shared geography. Nat Med 2018; 24(10): 1526-31.
[http://dx.doi.org/10.1038/s41591-018-0160-1] [PMID: 30150717]
[11]
Mima K, Cao Y, Chan AT, et al. Fusobacterium nucleatum in colorectal carcinoma tissue according to tumor location. Clin Transl Gastroenterol 2016; 7(11): e200.
[http://dx.doi.org/10.1038/ctg.2016.53] [PMID: 27811909]
[12]
Ahn J, Sinha R, Pei Z, et al. Human gut microbiome and risk for colorectal cancer. J Natl Cancer Inst 2013; 105(24): 1907-11.
[http://dx.doi.org/10.1093/jnci/djt300] [PMID: 24316595]
[13]
Kasai C, Sugimoto K, Moritani I, et al. Comparison of human gut microbiota in control subjects and patients with colorectal carcinoma in adenoma: Terminal restriction fragment length polymorphism and next-generation sequencing analyses. Oncol Rep 2016; 35(1): 325-33.
[http://dx.doi.org/10.3892/or.2015.4398] [PMID: 26549775]
[14]
Flemer B, Lynch DB, Brown JMR, et al. Tumour-associated and non-tumour-associated microbiota in colorectal cancer. Gut 2017; 66(4): 633-43.
[http://dx.doi.org/10.1136/gutjnl-2015-309595] [PMID: 26992426]
[15]
Raskov H, Burcharth J, Pommergaard HC. Linking gut microbiota to colorectal cancer. J Cancer 2017; 8(17): 3378-95.
[http://dx.doi.org/10.7150/jca.20497] [PMID: 29151921]
[16]
Klampfer L. Cytokines, inflammation and colon cancer. Curr Cancer Drug Targets 2011; 11(4): 451-64.
[http://dx.doi.org/10.2174/156800911795538066] [PMID: 21247378]
[17]
Li S, Konstantinov SR, Smits R, Peppelenbosch MP. Bacterial biofilms in colorectal cancer initiation and progression. Trends Mol Med 2017; 23(1): 18-30.
[http://dx.doi.org/10.1016/j.molmed.2016.11.004] [PMID: 27986421]
[18]
Kostic AD, Gevers D, Pedamallu CS, et al. Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. Genome Res 2012; 22(2): 292-8.
[http://dx.doi.org/10.1101/gr.126573.111] [PMID: 22009990]
[19]
Castellarin M, Warren RL, Freeman JD, et al. Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. Genome Res 2012; 22(2): 299-306.
[http://dx.doi.org/10.1101/gr.126516.111] [PMID: 22009989]
[20]
Shang FM, Liu HL. Fusobacterium nucleatum and colorectal cancer: A review. World J Gastrointest Oncol 2018; 10(3): 71-81.
[http://dx.doi.org/10.4251/wjgo.v10.i3.71] [PMID: 29564037]
[21]
Zackular JP, Baxter NT, Iverson KD, et al. The gut microbiome modulates colon tumorigenesis. MBio 2013; 4(6): e00692-13.
[http://dx.doi.org/10.1128/mBio.00692-13] [PMID: 24194538]
[22]
Ericsson AC, Akter S, Hanson MM, et al. Differential susceptibility to colorectal cancer due to naturally occurring gut microbiota. Oncotarget 2015; 6(32): 33689-704.
[http://dx.doi.org/10.18632/oncotarget.5604] [PMID: 26378041]
[23]
An J, Ha EM. Combination therapy of Lactobacillus plantarum supernatant and 5-fluouracil increases chemosensitivity in colorectal cancer cells. J Microbiol Biotechnol 2016; 26(8): 1490-503.
[http://dx.doi.org/10.4014/jmb.1605.05024] [PMID: 27221111]
[24]
Iida N, Dzutsev A, Stewart CA, et al. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science 2013; 342(6161): 967-70.
[http://dx.doi.org/10.1126/science.1240527] [PMID: 24264989]
[25]
Viaud S, Saccheri F, Mignot G, et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science 2013; 342(6161): 971-6.
[http://dx.doi.org/10.1126/science.1240537] [PMID: 24264990]
[26]
Sivan A, Corrales L, Hubert N, et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy. Science 2015; 350(6264): 1084-9.
[http://dx.doi.org/10.1126/science.aac4255] [PMID: 26541606]
[27]
Pennisi E. Biomedicine. Cancer therapies use a little help from microbial friends. Science 2013; 342(6161): 921.
[http://dx.doi.org/10.1126/science.342.6161.921] [PMID: 24264971]
[28]
Aarnoutse R, de Vos-Geelen JMPGM, Penders J, et al. Study protocol on the role of intestinal microbiota in colorectal cancer treatment: A pathway to personalized medicine 2.0. Int J Colorectal Dis 2017; 32(7): 1077-84.
[http://dx.doi.org/10.1007/s00384-017-2819-3] [PMID: 28444508]
[29]
Salminen S, Bouley C, Boutron M-C, et al. Functional food science and gastrointestinal physiology and function. Br J Nutr 1998; 80(S1) (Suppl. 1): S147-71.
[http://dx.doi.org/10.1079/BJN19980108] [PMID: 9849357]
[30]
FAO. Probiotics in food Health and nutritional properties and guidelines for evaluation. 2006.
[31]
Toscano M, De Grandi R, Pastorelli L, Vecchi M, Drago L. A consumer’s guide for probiotics: 10 golden rules for a correct use. Dig Liver Dis 2017; 49(11): 1177-84.
[http://dx.doi.org/10.1016/j.dld.2017.07.011] [PMID: 28830747]
[32]
Brady LJ, Gallaher DD, Busta FF. The role of probiotic cultures in the prevention of colon cancer. J Nutr 2000; 130(2) (Suppl.): 410S-4S.
[http://dx.doi.org/10.1093/jn/130.2.410S] [PMID: 10721916]
[33]
Yeung CY, Chan WT, Jiang CB, et al. Amelioration of chemotherapy-induced intestinal mucositis by orally administered probiotics in a mouse model. PLoS One 2015; 10(9): e0138746.
[http://dx.doi.org/10.1371/journal.pone.0138746] [PMID: 26406888]
[34]
Ishikawa H, Akedo I, Otani T, et al. Randomized trial of dietary fiber and Lactobacillus casei administration for prevention of colorectal tumors. Int J Cancer 2005; 116(5): 762-7.
[http://dx.doi.org/10.1002/ijc.21115] [PMID: 15828052]
[35]
Bowen JM, Stringer AM, Gibson RJ, Yeoh ASJ, Hannam S, Keefe DMK. VSL#3 probiotic treatment reduces chemotherapy-induced diarrhoea and weight loss. Cancer Biol Ther 2007; 6(9): 1445-50.
[http://dx.doi.org/10.4161/cbt.6.9.4622] [PMID: 17881902]
[36]
Salva S, Marranzino G, Villena J, Agüero G, Alvarez S. Probiotic Lactobacillus strains protect against myelosuppression and immunosuppression in cyclophosphamide-treated mice. Int Immunopharmacol 2014; 22(1): 209-21.
[http://dx.doi.org/10.1016/j.intimp.2014.06.017] [PMID: 24975836]
[37]
Mego M, Chovanec J, Vochyanova-Andrezalova I, et al. Prevention of irinotecan induced diarrhea by probiotics: A randomized double blind, placebo controlled pilot study. Complement Ther Med 2015; 23(3): 356-62.
[http://dx.doi.org/10.1016/j.ctim.2015.03.008] [PMID: 26051570]
[38]
Österlund P, Ruotsalainen T, Korpela R, Saxelin M, Ollus A, Valta P. Lactobacillus supplementation for diarrhoea related to chemotherapy of colorectal cancer: A randomised study. British Journal of Cancer 2007; 97: 1028-34.
[http://dx.doi.org/10.1038/sj.bjc.6603990]
[39]
Fuccio L, Guido A, Eusebi LH, et al. Effects of probiotics for the prevention and treatment of radiation-induced diarrhea. J Clin Gastroenterol 2009; 43(6): 506-13.
[http://dx.doi.org/10.1097/MCG.0b013e3181a1f59c] [PMID: 19398930]
[40]
Packey CD, Ciorba MA. Microbial influences on the small intestinal response to radiation injury. Curr Opin Gastroenterol 2010; 26(2): 88-94.
[http://dx.doi.org/10.1097/MOG.0b013e3283361927] [PMID: 20040865]
[41]
Kotzampassi K, Stavrou G, Damoraki G, et al. A four-probiotics regimen reduces postoperative complications after colorectal surgery: A randomized, double-blind, placebo-controlled study. World J Surg 2015; 39(11): 2776-83.
[http://dx.doi.org/10.1007/s00268-015-3071-z] [PMID: 25894405]
[42]
Krebs B. Prebiotic and synbiotic treatment before colorectal surgery-randomised double blind trial. Coll Antropol 2016; 40(1): 35-40.
[PMID: 27301235]
[43]
Mi H, Dong Y, Zhang B, et al. Bifidobacterium Infantis ameliorates chemotherapy-induced intestinal mucositis via regulating T cell immunity in colorectal cancer rats. Cell Physiol Biochem 2017; 42(6): 2330-41.
[http://dx.doi.org/10.1159/000480005] [PMID: 28848081]
[44]
Banys-Paluchowski M, Fehm T, Janni W, et al. Elevated serum RAS p21 is an independent prognostic factor in metastatic breast cancer. BMC Cancer 2018; 18(1): 541.
[http://dx.doi.org/10.1186/s12885-018-4282-0] [PMID: 29739347]
[45]
Singh J, Rivenson A, Tomita M, Shimamura S, Ishibashi N, Reddy BS. Bifidobacterium longum, a lactic acid-producing intestinal bacterium inhibits colon cancer and modulates the intermediate biomarkers of colon carcinogenesis. Carcinogenesis 1997; 18(4): 833-41.
[http://dx.doi.org/10.1093/carcin/18.4.833] [PMID: 9111222]
[46]
Walia S, Kamal R, Kanwar SS, Dhawan DK. Cyclooxygenase as a target in chemoprevention by probiotics during 1,2-dimethylhydrazine induced colon carcinogenesis in rats. Nutr Cancer 2015; 67(4): 603-11.
[http://dx.doi.org/10.1080/01635581.2015.1011788] [PMID: 25811420]
[47]
Kumar RS, Kanmani P, Yuvaraj N, et al. Lactobacillus plantarum AS1 isolated from south Indian fermented food Kallappam suppress 1,2-dimethyl hydrazine (DMH)-induced colorectal cancer in male Wistar rats. Appl Biochem Biotechnol 2012; 166(3): 620-31.
[http://dx.doi.org/10.1007/s12010-011-9453-2] [PMID: 22161238]
[48]
Wang CSE, Li WB, Wang HY, et al. VSL#3 can prevent ulcerative colitis-associated carcinogenesis in mice. World J Gastroenterol 2018; 24(37): 4254-62.
[http://dx.doi.org/10.3748/wjg.v24.i37.4254] [PMID: 30310258]
[49]
Ali MS, Hussein RM, Gaber Y, Hammam OA, Kandeil MA. Modulation of JNK-1/β-catenin signaling by Lactobacillus casei, inulin and their combination in 1,2-dimethylhydrazine-induced colon cancer in mice. RSC Advances 2019; 9(50): 29368-83.
[http://dx.doi.org/10.1039/C9RA04388H] [PMID: 35528422]
[50]
Chung IC, OuYang CN, Yuan SN, et al. Pretreatment with a heat-Killed probiotic modulates the NLRP3 inflammasome and attenuates colitis-associated colorectal cancer in mice. Nutrients 2019; 11(3): 516.
[http://dx.doi.org/10.3390/nu11030516] [PMID: 30823406]
[51]
Irecta-Nájera CA, del Rosario Huizar-López M, Casas-Solís J, Castro-Félix P, Santerre A. Protective effect of Lactobacillus casei on DMH-induced colon carcinogenesis in mice. Probiotics Antimicrob Proteins 2017; 9(2): 163-71.
[http://dx.doi.org/10.1007/s12602-017-9253-2] [PMID: 28316010]
[52]
Lee JY, Chu SH, Jeon JY, et al. Effects of 12 weeks of probiotic supplementation on quality of life in colorectal cancer survivors: A double-blind, randomized, placebo-controlled trial. Dig Liver Dis 2014; 46(12): 1126-32.
[http://dx.doi.org/10.1016/j.dld.2014.09.004] [PMID: 25442120]
[53]
Mörkl S, Lackner S, Meinitzer A, et al. Gut microbiota, dietary intakes and intestinal permeability reflected by serum zonulin in women. Eur J Nutr 2018; 57(8): 2985-97.
[http://dx.doi.org/10.1007/s00394-018-1784-0] [PMID: 30043185]
[54]
Liu ZH, Huang MJ, Zhang XW, et al. The effects of perioperative probiotic treatment on serum zonulin concentration and subsequent postoperative infectious complications after colorectal cancer surgery: A double-center and double-blind randomized clinical trial. Am J Clin Nutr 2013; 97(1): 117-26.
[http://dx.doi.org/10.3945/ajcn.112.040949] [PMID: 23235200]
[55]
Fu J, Xu Y, Yang Y, Liu Y, Ma L, Zhang Y. Aspirin suppresses chemoresistance and enhances antitumor activity of 5-Fu in 5-Fu-resistant colorectal cancer by abolishing 5-Fu-induced NF-κB activation. Sci Rep 2019; 9(1): 16937.
[http://dx.doi.org/10.1038/s41598-019-53276-1] [PMID: 31729451]
[56]
Cheng H, Zhao L, Ju Z, et al. Effects of 10.6-μm laser moxibustion and electroacupuncture at ST36 in a 5-Fu-induced diarrhea rat model. Support Care Cancer 2021; 29(5): 2561-9.
[http://dx.doi.org/10.1007/s00520-020-05788-0] [PMID: 32959156]
[57]
Gao Z, Guo B, Gao R, Zhu Q, Wu W, Qin H. Probiotics modify human intestinal mucosa-associated microbiota in patients with colorectal cancer. Mol Med Rep 2015; 12(4): 6119-27.
[http://dx.doi.org/10.3892/mmr.2015.4124] [PMID: 26238090]
[58]
Chang SC, Shen MH, Liu CY, Pu CM, Hu JM, Huang CJ. A gut butyrate-producing bacterium Butyricicoccus pullicaecorum regulates short-chain fatty acid transporter and receptor to reduce the progression of 1,2-dimethylhydrazine‑associated colorectal cancer. Oncol Lett 2020; 20(6): 327.
[http://dx.doi.org/10.3892/ol.2020.12190] [PMID: 33101496]
[59]
Hradicka P, Beal J, Kassayova M, Foey A, Demeckova V. A novel lactic acid bacteria mixture: Macrophage-targeted prophylactic intervention in colorectal cancer management. Microorganisms 2020; 8(3): 387.
[http://dx.doi.org/10.3390/microorganisms8030387]
[60]
Sharma M, Shukla G. Administration of metabiotics extracted from probiotic Lactobacillus rhamnosus MD 14 inhibit experimental colorectal carcinogenesis by targeting Wnt/β-catenin pathway. Front Oncol 2020; 10: 746.
[http://dx.doi.org/10.3389/fonc.2020.00746] [PMID: 32670864]
[61]
Parisa A, Roya G, Mahdi R, Shabnam R, Maryam E, Malihe T. Anti-cancer effects of Bifidobacterium species in colon cancer cells and a mouse model of carcinogenesis. PLoS One 2020; 15(5): e0232930.
[http://dx.doi.org/10.1371/journal.pone.0232930] [PMID: 32401801]
[62]
Oh NS, Lee JY, Kim YT, Kim SH, Lee JH. Cancer-protective effect of a synbiotic combination between Lactobacillus gasseri 505 and a Cudrania tricuspidata leaf extract on colitis-associated colorectal cancer. Gut Microbes 2020; 12(1): 1785803.
[http://dx.doi.org/10.1080/19490976.2020.1785803] [PMID: 32663105]
[63]
Zhou M, Yuan W, Yang B, Pei W, Ma J, Feng Q. Clostridium butyricum inhibits the progression of colorectal cancer and alleviates intestinal inflammation Via the myeloid differentiation factor 88 (MyD88)-nuclear factor-kappa B (NF-κB) signaling pathway. Ann Transl Med 2022; 10(8): 478-8.
[http://dx.doi.org/10.21037/atm-22-1670] [PMID: 35571406]
[64]
Liu J, Wang S, Yi R, Long X, Zhao X. Effect of Lactobacillus fermentum ZS40 on the NF-κB signaling pathway in an azomethane-dextran sulfate sodium-induced colon cancer mouse model. Front Microbiol 2022; 13: 953905.
[http://dx.doi.org/10.3389/fmicb.2022.953905]
[65]
Park IJ, Lee JH, Kye BH, et al. Effects of probiotics on the symptoms and surgical outcomes after anterior resection of colon cancer (POSTCARE): A randomized, double-blind, placebo-controlled trial. J Clin Med 2020; 9(7): 2181.
[http://dx.doi.org/10.3390/jcm9072181]
[66]
Shi Y, Meng L, Zhang C, Zhang F, Fang Y. Extracellular vesicles of Lacticaseibacillus paracasei PC-H1 induce colorectal cancer cells apoptosis Via PDK1/AKT/Bcl-2 signaling pathway. Microbiol Res 2022; 255: 126921.
[http://dx.doi.org/10.1016/j.micres.2021.126921] [PMID: 34839170]
[67]
Aindelis G, Tiptiri-Kourpeti A, Lampri E, Spyridopoulou K, Lamprianidou E, Kotsianidis I, et al. Immune responses raised in an experimental colon carcinoma model following oral administration of Lactobacillus casei. Cancers (Basel) 2020; 12(2): 368.
[http://dx.doi.org/10.3390/cancers12020368]
[68]
Hadad SEL, Alsolami M, Aldahlawi A, et al. In vivo evidence: Repression of mucosal immune responses in mice with colon cancer following sustained administration of Streptococcus thermophiles. Saudi J Biol Sci 2021; 28(8): 4751-61.
[http://dx.doi.org/10.1016/j.sjbs.2021.04.090] [PMID: 34354463]
[69]
Xu H, Hiraishi K, Kurahara LH, et al. Inhibitory effects of breast milk-derived lactobacillus rhamnosus probio-m9 on colitis-associated carcinogenesis by restoration of the gut microbiota in a mouse model. Nutrients 2021; 13(4): 1143.
[http://dx.doi.org/10.3390/nu13041143] [PMID: 33808480]
[70]
Ma F, Sun M, Song Y, et al. Lactiplantibacillus plantarum-12 alleviates inflammation and colon cancer symptoms in AOM/DSS-treated mice through modulating the intestinal microbiome and metabolome. Nutrients 2022; 14(9): 1916.
[http://dx.doi.org/10.3390/nu14091916] [PMID: 35565884]
[71]
Guo Y, Zhang T, Gao J, et al. Lactobacillus acidophilus CICC 6074 inhibits growth and induces apoptosis in colorectal cancer cells in vitro and in HT-29 cells induced-mouse model. J Funct Foods 2020; 75: 104290.
[http://dx.doi.org/10.1016/j.jff.2020.104290]
[72]
Sugimura N, Li Q, Chu ESH, et al. Lactobacillus gallinarum modulates the gut microbiota and produces anti-cancer metabolites to protect against colorectal tumourigenesis. Gut 2022; 71(10): 2011-21.
[http://dx.doi.org/10.1136/gutjnl-2020-323951] [PMID: 34937766]
[73]
Benito I, Encío IJ, Milagro FI, Alfaro M, Martínez‐peñuela A, Barajas M, et al. Microencapsulated Bifidobacterium bifidum and Lactobacillus gasseri in combination with quercetin inhibit colorectal cancer development in ApcMin/+ mice. Int J Mol Sci 2021; 22(9): 4906.
[http://dx.doi.org/10.3390/ijms22094906]
[74]
Valadez-Bustos N, Escamilla-Silva EM, García-Vázquez FJ, Gallegos-Corona MA, Amaya-Llano SL, Ramos-Gómez M. Oral administration of microencapsulated B. longum BAA-999 and Lycopene Modulates IGF-1/IGF-1R/IGFBP3 protein expressions in a colorectal murine model. Int J Mol Sci 2019; 20(17): 4275.
[http://dx.doi.org/10.3390/ijms20174275]
[75]
Jam S, Morshedi M, Khosroushahi AY, Eftekharsadat AT, Alipour M, Alipour B. Preventive and tumor-suppressive effects of Lactobacillus paracasei X12 in rat model of colorectal cancer. Iran J Pharm Res 2020; 19(4): 330-42.
[http://dx.doi.org/10.22037/IJPR.2019.112135.13547]
[76]
Yue Y, Ye K, Lu J, et al. Probiotic strain Lactobacillus plantarum YYC-3 prevents colon cancer in mice by regulating the tumour microenvironment. Biomed Pharmacother 2020; 127: 110159.
[http://dx.doi.org/10.1016/j.biopha.2020.110159] [PMID: 32353824]
[77]
Bi Z, Cui E, Yao Y, et al. Recombinant Bifidobacterium longum carrying endostatin protein alleviates dextran sodium sulfate-induced colitis and colon cancer in rats. Front Microbiol 2022; 13: 927277.
[http://dx.doi.org/10.3389/fmicb.2022.927277] [PMID: 35847065]
[78]
Saito Y, Hinoi T, Adachi T, et al. Synbiotics suppress colitis-induced tumorigenesis in a colon-specific cancer mouse model. PLoS One 2019; 14(6): e0216393.
[http://dx.doi.org/10.1371/journal.pone.0216393] [PMID: 31242213]
[79]
Shang F, Jiang X, Wang H, et al. The inhibitory effects of probiotics on colon cancer cells: In vitroo and in vivo studies. J Gastrointest Oncol 2020; 11(6): 1224-32.
[http://dx.doi.org/10.21037/jgo-20-573] [PMID: 33456995]
[80]
Polakowski CB, Kato M, Preti VB, Schieferdecker MEM, Ligocki Campos AC. Impact of the preoperative use of synbiotics in colorectal cancer patients: A prospective, randomized, double-blind, placebo-controlled study. Nutrition 2019; 58: 40-6.
[http://dx.doi.org/10.1016/j.nut.2018.06.004] [PMID: 30278428]
[81]
Bajramagic S, Hodzic E, Mulabdic A, Holjan S, Vincevic S. S, Rovcanin A. Usage of probiotics and its clinical significance at surgically treated patients sufferig from colorectal carcinoma. Med Arch 2019; 73(5): 316-20.
[http://dx.doi.org/10.5455/medarh.2019.73.316-320]
[82]
Khodaii Z, Mehrabani N. M, Khalighfard S, Ghandian Z. M, Gharghi M, Khori V. Novel targets in rectal cancer by considering lncRNA–miRNA–mRNA network in response to Lactobacillus acidophilus consumption: A randomized clinical trial. Scientific Reports 2022; 12(1)
[http://dx.doi.org/10.1038/s41598-022-13297-9]
[83]
Zaharuddin L, Mokhtar NM, Muhammad N. KN, Raja Ali RA. A randomized double-blind placebo-controlled trial of probiotics in post-surgical colorectal cancer. BMC Gastroenterol 2019; 19(1): 131.
[http://dx.doi.org/10.1186/s12876-019-1047-4] [PMID: 31340751]
[84]
Papaliagkas V, Anogianaki A, Anogianakis G, Ilonidis G. The proteins and the mechanisms of apoptosis: A mini-review of the fundamentals. Hippokratia 2007; 11(3): 108-13.
[PMID: 19582203]
[85]
Jan G, Belzacq AS, Haouzi D, et al. Propionibacteria induce apoptosis of colorectal carcinoma cells via short-chain fatty acids acting on mitochondria. Cell Death Differ 2002; 9(2): 179-88.
[http://dx.doi.org/10.1038/sj.cdd.4400935]
[86]
Thirabunyanon M, Hongwittayakorn P. Potential probiotic lactic acid bacteria of human origin induce antiproliferation of colon cancer cells via synergic actions in adhesion to cancer cells and short-chain fatty acid bioproduction. Appl Biochem Biotechnol 2013; 169(2): 511-25.
[http://dx.doi.org/10.1007/s12010-012-9995-y] [PMID: 23239414]
[87]
Cousin FJ, Jouan-Lanhouet S, Théret N, et al. The probiotic Propionibacterium freudenreichii as a new adjuvant for TRAIL-based therapy in colorectal cancer. Oncotarget 2016; 7(6): 7161-78.
[http://dx.doi.org/10.18632/oncotarget.6881] [PMID: 26771233]
[88]
Lazar V, Ditu LM, Pircalabioru GG, et al. Aspects of gut microbiota and immune system interactions in infectious diseases, immunopathology, and cancer. Front Immunol 2018; 9: 1830.
[http://dx.doi.org/10.3389/fimmu.2018.01830] [PMID: 30158926]
[89]
Ning Y, Manegold PC, Hong YK, et al. Interleukin-8 is associated with proliferation, migration, angiogenesis and chemosensitivity in vitro and In vivo in colon cancer cell line models. Int J Cancer 2011; 128(9): 2038-49.
[http://dx.doi.org/10.1002/ijc.25562] [PMID: 20648559]
[90]
Lopez M, Li N, Kataria J, Russell M, Neu J. Live and ultraviolet-inactivated Lactobacillus rhamnosus GG decrease flagellin-induced interleukin-8 production in Caco-2 cells. J Nutr 2008; 138(11): 2264-8.
[http://dx.doi.org/10.3945/jn.108.093658] [PMID: 18936229]
[91]
Lee NK, Son SH, Jeon EB, Jung GH, Lee JY, Paik HD. The prophylactic effect of probiotic Bacillus polyfermenticus KU3 against cancer cells. J Funct Foods 2015; 14: 513-8.
[http://dx.doi.org/10.1016/j.jff.2015.02.019]
[92]
Kim Y, Lee D, Kim D, et al. Inhibition of proliferation in colon cancer cell lines and harmful enzyme activity of colon bacteria by Bifidobacterium adolescentis SPM0212. Arch Pharm Res 2008; 31(4): 468-73.
[http://dx.doi.org/10.1007/s12272-001-1180-y] [PMID: 18449504]
[93]
Chen ZF, Ai LY, Wang JL, Ren LL, Yu YN, Xu J. Probiotics Clostridium butyricum and Bacillus subtilis ameliorate intestinal tumorigenesis. Future Microbiol 2015; 10(9): 1433-45.
[http://dx.doi.org/10.2217/fmb.15.66]
[94]
DeGruttola AK, Low D, Mizoguchi A, Mizoguchi E. Current understanding of dysbiosis in disease in human and animal models. Inflamm Bowel Dis 2016; 22(5): 1137-50.
[http://dx.doi.org/10.1097/MIB.0000000000000750] [PMID: 27070911]
[95]
Kaźmierczak-Siedlecka K, Daca A, Fic M, van de Wetering T, Folwarski M, Makarewicz W. Therapeutic methods of gut microbiota modification in colorectal cancer management – fecal microbiota transplantation, prebiotics, probiotics, and synbiotics. Gut Microbes 2020; 11(6): 1518-30.
[http://dx.doi.org/10.1080/19490976.2020.1764309] [PMID: 32453670]
[96]
Lin C, Cai X, Zhang J, et al. Role of gut microbiota in the development and treatment of colorectal cancer. Digestion 2019; 100(1): 72-8.
[http://dx.doi.org/10.1159/000494052] [PMID: 30332668]
[97]
Weiss GA, Hennet T. Mechanisms and consequences of intestinal dysbiosis. Cell Mol Life Sci 2017; 74(16): 2959-77.
[http://dx.doi.org/10.1007/s00018-017-2509-x] [PMID: 28352996]
[98]
King CH, Desai H, Sylvetsky AC, et al. Baseline human gut microbiota profile in healthy people and standard reporting template. PLoS One 2019; 14(9): e0206484.
[http://dx.doi.org/10.1371/journal.pone.0206484] [PMID: 31509535]
[99]
Groschwitz KR, Hogan SP. Intestinal barrier function: Molecular regulation and disease pathogenesis. J Allergy Clin Immunol 2009; 124(1): 3-20.
[http://dx.doi.org/10.1016/j.jaci.2009.05.038] [PMID: 19560575]
[100]
Elhaseen E E, Ad A M, Jan D, Harm-Jan P, Daisy M J. Short-chain fatty acids activate AMP-activated protein kinase and ameliorate ethanol-induced intestinal barrier dysfunction in Caco-2 cell monolayers. J Nutr 2013; 143(12): 1872-81.
[http://dx.doi.org/10.3945/jn.113.179549] [PMID: 24132573]
[101]
Markowiak-Kopeć P, Śliżewska K. The effect of probiotics on the production of short-chain fatty acids by human intestinal microbiome. Nutrients 2020; 12(4): 1107.
[http://dx.doi.org/10.3390/nu12041107] [PMID: 32316181]
[102]
Kelly CJ, Zheng L, Campbell EL, et al. Crosstalk between microbiota-derived short-chain fatty acids and intestinal epithelial HIF augments tissue barrier function. Cell Host Microbe 2015; 17(5): 662-71.
[http://dx.doi.org/10.1016/j.chom.2015.03.005] [PMID: 25865369]
[103]
Tong L, Wang Y, Wang Z, et al. Propionate ameliorates dextran sodium sulfate-induced colitis by improving intestinal barrier function and reducing inflammation and oxidative stress. Front Pharmacol 2016; 7: 253.
[http://dx.doi.org/10.3389/fphar.2016.00253] [PMID: 27574508]
[104]
Chen T, Kim CY, Kaur A, et al. Dietary fibre-based SCFA mixtures promote both protection and repair of intestinal epithelial barrier function in a CaCo-2 cell model. Food Funct 2017; 8(3): 1166-73.
[http://dx.doi.org/10.1039/C6FO01532H] [PMID: 28174773]
[105]
Bron PA, Kleerebezem M, Brummer RJ, et al. Can probiotics modulate human disease by impacting intestinal barrier function? Br J Nutr 2017; 117(1): 93-107.
[http://dx.doi.org/10.1017/S0007114516004037] [PMID: 28102115]
[106]
Ohland CL, MacNaughton WK. Probiotic bacteria and intestinal epithelial barrier function. Am J Physiol Gastrointest Liver Physiol 2010; 298(6): G807-19.
[http://dx.doi.org/10.1152/ajpgi.00243.2009] [PMID: 20299599]
[107]
Konishi H, Fujiya M, Tanaka H, et al. Probiotic-derived ferrichrome inhibits colon cancer progression via JNK-mediated apoptosis. Nat Commun 2016; 7: 12365.
[http://dx.doi.org/10.1038/ncomms12365]
[108]
Chen ZY, Hsieh YM, Huang CC, Tsai CC. Inhibitory effects of probiotic Lactobacillus on the growth of human colonic carcinoma cell line HT-29. Molecules 2017; 22(1): 107.
[http://dx.doi.org/10.3390/molecules22010107]
[109]
Saxami G, Karapetsas A, Lamprianidou E, et al. Two potential probiotic lactobacillus strains isolated from olive microbiota exhibit adhesion and anti-proliferative effects in cancer cell lines. J Funct Foods 2016; 24: 461-71.
[http://dx.doi.org/10.1016/j.jff.2016.04.036]
[110]
Eslami M, Yousefi B, Kokhaei P, et al. Importance of probiotics in the prevention and treatment of colorectal cancer. J Cell Physiol 2019; 234(10): 17127-43.
[http://dx.doi.org/10.1002/jcp.28473] [PMID: 30912128]
[111]
Nagao M, Sugimura T. Carcinogenic factors in food with relevance to colon cancer development. Mutat Res 1993; 290(1): 43-51.
[http://dx.doi.org/10.1016/0027-5107(93)90031-A] [PMID: 7694098]
[112]
Cross AJ, Sinha R. Meat-related mutagens/carcinogens in the etiology of colorectal cancer. Environ Mol Mutagen 2004; 44(1): 44-55.
[http://dx.doi.org/10.1002/em.20030] [PMID: 15199546]
[113]
Shoukat S. Potential anti-carcinogenic effect of probiotic and lactic acid bacteria in detoxification of benzo[a]pyrene: A review. Trends Food Sci Technol 2020; 99: 450-9.
[http://dx.doi.org/10.1016/j.tifs.2020.02.029]
[114]
Li L, Hong K, Sun Q, et al. Probiotics for preventing upper respiratory tract infections in adults: A systematic review and meta-analysis of randomized controlled trials. Evid Based Complement Alternat Med 2020; 2020: 1-8.
[http://dx.doi.org/10.1155/2020/8734140] [PMID: 33293995]
[115]
Ohishi A, Takahashi S, Ito Y, et al. Bifidobacterium septicemia associated with postoperative probiotic therapy in a neonate with omphalocele. J Pediatr 2010; 156(4): 679-81.
[http://dx.doi.org/10.1016/j.jpeds.2009.11.041] [PMID: 20303445]
[116]
Besselink MGH, van Santvoort HC, Buskens E, et al. Probiotic prophylaxis in predicted severe acute pancreatitis: A randomised, double-blind, placebo-controlled trial. Lancet 2008; 371(9613): 651-9.
[http://dx.doi.org/10.1016/S0140-6736(08)60207-X] [PMID: 18279948]
[117]
Anadón A, Ares I, Martínez-Larrañaga MR, Martínez MA. Probiotics: Safety and Toxicity Considerations.Nutraceuticals. Amsterdam: Elsevier 2016; pp. 777-853.
[http://dx.doi.org/10.1016/B978-0-12-821038-3.00065-3]
[118]
Mikov M, Đanić M, Pavlović N, et al. Potential applications of gliclazide in treating type 1 diabetes mellitus: Formulation with bile acids and probiotics. Eur J Drug Metab Pharmacokinet 2018; 43(3): 269-80.
[http://dx.doi.org/10.1007/s13318-017-0441-y] [PMID: 29039071]
[119]
Imperial ICVJ, Ibana JA. Addressing the antibiotic resistance problem with probiotics: Reducing the risk of its double-edged sword effect. Front Microbiol 2016; 7: 1983.
[http://dx.doi.org/10.3389/fmicb.2016.01983] [PMID: 28018315]
[120]
Salvana EMT, Frank M. Lactobacillus endocarditis: Case report and review of cases reported since 1992. J Infect 2006; 53(1): e5-e10.
[http://dx.doi.org/10.1016/j.jinf.2005.10.005] [PMID: 16307799]
[121]
Rao SSC, Rehman A, Yu S, de Andino NM. Brain fogginess, gas and bloating: A link between SIBO, probiotics and metabolic acidosis. Clin Transl Gastroenterol 2018; 9(6): e162.
[http://dx.doi.org/10.1038/s41424-018-0030-7] [PMID: 29915215]
[122]
El Aidy S, van den Bogert B, Kleerebezem M. The small intestine microbiota, nutritional modulation and relevance for health. Curr Opin Biotechnol 2015; 32: 14-20.
[http://dx.doi.org/10.1016/j.copbio.2014.09.005] [PMID: 25308830]
[123]
Alvarez MA, Moreno-Arribas MV. The problem of biogenic amines in fermented foods and the use of potential biogenic amine-degrading microorganisms as a solution. Trends Food Sci Technol 2014; 39(2): 146-55.
[http://dx.doi.org/10.1016/j.tifs.2014.07.007]
[124]
Pradhan D, Mallappa RH, Grover S. Comprehensive approaches for assessing the safety of probiotic bacteria. Food Control 2020; 108: 106872.
[http://dx.doi.org/10.1016/j.foodcont.2019.106872]
[125]
Probiotics Market by Size. Probiotics market by strain (Bacillus), by product type (dairy food {Yogurt}, baked food}, animal feed), by form (liquid), by sales channel (Super Markets, Pharmacies), by end-user (human {adults, senior}, animal), and geography - global forecast To 2027. 2021. Available From: https://www.meticulousresearch.com/product/probiotics-market-5113
[126]
Arora M, Baldi A. Regulatory categories of probiotics across the globe: A review representing existing and recommended categorization. Indian J Med Microbiol 2015; 33 (Suppl.): S2-S10.
[http://dx.doi.org/10.4103/0255-0857.150868] [PMID: 25657150]

Rights & Permissions Print Cite
Article Metrics
14
1
Wayfinder Image
Open Access Journals Promotions
© 2024 Bentham Science Publishers | Privacy Policy